Results about: treatment

Donate to the medicine of the future

Coinciding with #GivingTuesday, today IRB Barcelona is launching its donation campaign for the forthcoming holiday season.

Basic research paves the way towards the medicine of the future. Donations made to research speed up discoveries

P38MAM

New combination therapy for breast tumours, with selection marker

IRB Barcelona paves the way to the use of immunotherapy to treat aggressive colon tumours and their metastasis

A team headed by ICREA researcher Eduard Batlle discovers that immune system-stimulating treatments combined with a TGF-beta inhibitor are effective against colon cancer.

The researchers developed a mouse model that mimics advanced human colon cancer. This model has allowed them to study the immune system response for the first time.

An international consortium identifies the breast cancer patients who would benefit from a treatment to prevent metastasis

A study published in the Lancet Oncology by an international team led by Prof Rob E. Coleman (University of Sheffield) and Prof Roger R. Gomis (IRB Barcelona) identifies the effect of MAF amplification on the outcome of treatment with adjuvant zoledronic acid in early breast cancer.

This new knowledge may be key to the early detection of patients who would benefit from zoledronic acid and those who should be spared, and both reduce disease recurrence and deaths from breast cancer.

Inbiomotion, an IRB Barcelona spin off company and financed by venture investors Ysios Capital and Caixa Capital Risc, will soon start a confirmatory trial.